MedPath

Vivoryon Therapeutics N.V.

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

9

Active:4
Completed:4

Trial Phases

2 Phases

Phase 1:5
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (55.6%)
Phase 2
4 (44.4%)

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

Phase 2
Completed
Conditions
Mild Cognitive Impairment Due to AD
Early Alzheimers Disease
Interventions
Drug: Placebo
First Posted Date
2020-08-04
Last Posted Date
2024-03-12
Lead Sponsor
Vivoryon Therapeutics N.V.
Target Recruit Count
259
Registration Number
NCT04498650
Locations
🇩🇰

Sanos Clinics, Vejle, Denmark

🇩🇪

Charité - Universitätsmedizin Berlin, Berlin, Germany

🇩🇪

Universitätsklinikum Schleswig-Holstein (UKSH), Klinik für Neurologie, Kiel, Germany

and more 14 locations

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

Phase 2
Terminated
Conditions
Alzheimer Disease
Interventions
Other: Placebo
First Posted Date
2019-04-18
Last Posted Date
2025-07-08
Lead Sponsor
Vivoryon Therapeutics N.V.
Target Recruit Count
112
Registration Number
NCT03919162
Locations
🇺🇸

Barrow Neurological Institute, Phoenix, Arizona, United States

🇺🇸

Banner Sun Health Research Institute, Sun City, Arizona, United States

🇺🇸

The Neuron Clinic, Chula Vista, California, United States

and more 19 locations

Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Other: Placebo
Drug: PQ912 oral
First Posted Date
2015-03-17
Last Posted Date
2017-06-01
Lead Sponsor
Vivoryon Therapeutics N.V.
Target Recruit Count
120
Registration Number
NCT02389413
Locations
🇧🇪

Ziekenhuis Netwerk Antwerpen / Geheugenkliniek, Hoboken, Belgium

🇫🇮

Kliininen tutkimuskeskus, Kuopio, Finland

🇫🇮

Oulu University Hospital, Oulu, Finland

and more 20 locations

Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole

Phase 1
Completed
Conditions
Pharmacologic Action
Healthy Volunteers
Interventions
First Posted Date
2014-07-15
Last Posted Date
2015-10-21
Lead Sponsor
Vivoryon Therapeutics N.V.
Target Recruit Count
18
Registration Number
NCT02190708
Locations
🇬🇧

Covance Clinical Research Unit Ltd, Leeds, United Kingdom

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.